Trial Profile
Diarrhea-Predominant Irritable Bowel Syndrome in Persian Gulf Veterans.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2018
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Blind loop syndrome; Irritable bowel syndrome
- Focus Therapeutic Use
- 04 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
- 28 Jun 2011 Planned end date changed from 1 Aug 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 28 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.